Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nephrology

• Publication date

  2007-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1440-1797.2006.00761.xPMID 17371332
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.

  2005cited by this paper
• Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase.

  2005cited by this paper
• Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.

  2005cited by this paper
• Pure red-cell aplasia and epoetin therapy.

  2004cited by this paper
• Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

  2004cited by this paper
• Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron‐replete haemodialysis patients

  2004cited by this paper
• Epoetin in haemodialysis patients: impact of change from subcutaneous to intravenous routes of administration

  2004cited by this paper
• Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

  2004cited by this paper
• Regional variability in anaemia management and haemoglobin in the US.

  2003cited by this paper
• Current incidence, treatment patterns and outcome of end‐stage renal disease among indigenous groups in Australia and New Zealand

  2003cited by this paper
• Effect of variability in anemia management on hemoglobin outcomes in ESRD.

  2003cited by this paper
• Intravenous administration of epoetin in haemodialysis patients.

  2003cited by this paper
• Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.

  2002cited by this paper
• Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.

  1998cited by this paper
• SUBCUTANEOUS COMPARED WITH INTRAVENOUS EPOETIN IN PATIENTS RECEIVING HEMODIALYSIS

  1998cited by this paper
• Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients IV and SC erythropoietin

  1996cited by this paper
• Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.

  1995cited by this paper
• The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.

  1992cited by this paper
• Quality of life and hematocrit level.

  1992cited by this paper
• Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.

  1992cited by this paper
• The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

  1990cited by this paper
• Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers.

  1990cited by this paper
• Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.

  1989cited by this paper

• A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction.

  2013cites this paper
• Cost Analysis of an Intravenous to Subcutaneous Epoetin α Conversion

  2013cites this paper
• Administration of the same dose of epoetin-beta intravenously and subcutaneously to patients with renal anaemia

  2011influential citation
• [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].

  2009cites this paper
• Enfermedad renal crónica asociada a diacetilmorfina (heroína)

  2008cites this paper
• Increased erythropoietin-alpha dose when switching from subcutaneous to intravenous administration: effect of serum albumin.

  2008cites this paper
• Understanding epoetin use: databases or clinical trials?

  2007cites this paper
• Understanding epoetin use: Databases or clinical trials? (Editorial)

  2007cites this paper